Boğaziçi CT3
Boğaziçi University Center for Targeted Therapy Technologies (Boğaziçi CT3)
Boğaziçi CT3 obtained legal entity status as of 10.09.2024 as a thematic research infrastructure within the scope of Article 2 of Law No. 6550 on Supporting Research Infrastructures. Within this framework, the existing infrastructure units, instrument park, know-how, and ongoing activities of the Boğaziçi University Life Sciences and Technologies Application and Research Center (Boğaziçi LifeSci) have been restructured under an integrated framework within Boğaziçi CT3 and brought under centralized coordination.
The Center is located within the Deep Tech Base on Boğaziçi University’s Kandilli Campus, and it centrally manages from this location all processes related to the operation, planning, and provision of the inherited infrastructure units and instruments to stakeholders. Boğaziçi CT3 provides infrastructure support for research, development, testing and analysis, prototyping, and validation activities through collaborations with academic units, public institutions, the private sector, and the entrepreneurship ecosystem.
To strengthen quality, traceability, and international alignment in its testing and analysis activities, Boğaziçi CT³ has been authorized under an OECD Good Laboratory Practice (GLP) compliance statement. As of 10.12.2025, this authorization has been granted under the headings of Physico-Chemical Tests, Residue Studies, and Analytical and Clinical Chemical Tests. Within this scope, the Center serves as a solution partner for GLP-based studies, including—among others—Extractables & Leachables (E&L) studies for medical devices, pharmacokinetic (PK) studies, nitrosamine impurity determination, elemental impurity analyses, residual solvent analyses, and API and related impurity analyses.
Through its activity areas that intersect with the pharmaceutical and medical device sectors—identified as priority sectors in the 11th and 12th Development Plans—Boğaziçi CT3 aims to accelerate R&D and commercialization efforts in targeted therapeutics, biotechnological products, and biomedical devices. By specializing in the “Targeted Therapy Technologies” vertical, the Center seeks to reinforce critical weaknesses identified in the national value chain along the pathway from research ideas to clinical readiness, and to address gaps in the preclinical stages of translational research.
In this context, Boğaziçi CT3 offers an integrated infrastructure that supports all phases of the R&D cycle—from idea to product, and from preclinical studies to pilot production. Through its Testing and Analysis Unit, Industrial Services Testing and Analysis Unit (GLP-certified), Cleanroom and Medical Device Development Unit, Experimental Animal Imaging Unit, and other relevant units and platforms, the Center serves research activities across a wide range of fields, including drug delivery systems, molecular imaging, biosensors, vaccine technologies, and biomaterials.
As an Istanbul-based health technologies innovation platform (İSEK), Boğaziçi CT3 promotes interdisciplinary research by integrating academia–industry–entrepreneurship–public collaborations and contributes to strengthening solution development capacity for the sector. Hosting projects supported by national and international funding programs such as TÜBİTAK and the European Union (Horizon Europe), the Center aims to accelerate the transition from laboratory to application by supporting ventures through mechanisms such as preclinical testing and validation processes and investor matchmaking.
The primary mission of Boğaziçi CT3 is to make an institutional contribution to the creation of a sustainable, accessible, and high value-added innovation environment in health technologies—one that strengthens the interaction between academic knowledge and deep technology, and clinical and commercial applications.